Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?

Bibliography

• The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Severs PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al: for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Eng J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-57
   PubMed Web of Science ®Google Scholar
• Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular models to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10-17
   PubMedGoogle Scholar
• Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003;63:2449-72
   PubMed Web of Science ®Google Scholar
• Sironi G, Montagna E, Greto L, et al. Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs. Arzneimittelforschung 1996;46:256-61
   PubMed Web of Science ®Google Scholar
• Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003;37:203-12
   PubMed Web of Science ®Google Scholar
• Romito R, Pansini MI, Perticone F, et al. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens 2003;5:249-53
   PubMedGoogle Scholar
• Leonetti G, Magnani B, Pessina AC, et al.; COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40
   PubMed Web of Science ®Google Scholar
• Barrios V, Navarro A, Esteras A, et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002;11:95-100
   PubMed Web of Science ®Google Scholar
• Burnier M, Gasser UE. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007;8(14):2215-23
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, de la Figuera M, et al. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study. Cardiovasc Ther 2008;26:2-9
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Navarro A, et al: LAURA Investigators. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract 2006;60(11):1364-70
   PubMed Web of Science ®Google Scholar
• Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1(3):173-82
   PubMedGoogle Scholar
• Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr Metab 2004;17:259-66
   PubMedGoogle Scholar
• Sasaki T, Maruyama H, Kase Y, et al. Antianginal effects of lercanidipine on the vasopressin or metacholine induced anginal models in rats. Biol Pharm Bull 2005;28(5):811-6
   PubMed Web of Science ®Google Scholar
• Acanfora D, Gheorghiade M, Trojano L, et al. A randomized, double-blind comparison of lercanidipine 10 and 20mg in patients with stable effort angina: clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring. Am J Ther 2004;11(6):423-32
   PubMed Web of Science ®Google Scholar
• Borghi C, Prandin MG, Dormi A, Ambrosioni E. Study group of the regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003;(Suppl 1):14-21
   Web of Science ®Google Scholar
• Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003;21:1003-10
   PubMed Web of Science ®Google Scholar
• Fogari R, Malamani GD, Zoppi A, et al. Comparative effect of lercanidipine and nifedipine Gastrointestinal Therapeutic System on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res Clin Exp 2000;61:850-62
   Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003;16:1357-69
   Web of Science ®Google Scholar
• Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003;21(10):1969-73
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Observations on the safety of lercanidipine: adverse events from placebo-controlled trials. Am J Hypertens 2002;15:58A-9A
   PubMed Web of Science ®Google Scholar
• Burnier M, Brown RE, Ong SH, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 2009;63(5):790-8
   PubMed Web of Science ®Google Scholar
• Quan A, Chavanu K, Merkel J. A review of the efficacy of fixeddose combinations of olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006;6:103-13
   PubMedGoogle Scholar
• Stergiou G, Makris T, Papavasiliou M, et al. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocking monotherapy. Hypertens 2005;23:883-9
   Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
   PubMed Web of Science ®Google Scholar
• Cleophas TJ, van Ouwekerk BM, van der Meulen J, et al. Diabetics with hypertension not controlled with ACE-inhibitors: alternate therapies. Angiology 2001;52(7):469-75
   PubMed Web of Science ®Google Scholar
• Grandi AM, Solbiati F, Laurita E, et al. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am J Hypertens 2008;21(2):231-7
   PubMed Web of Science ®Google Scholar
• Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24(1):185-92
   PubMed Web of Science ®Google Scholar
• Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007;67(1):95-106
   PubMed Web of Science ®Google Scholar
• Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;21(12):917-24
   PubMed Web of Science ®Google Scholar
• Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005;1:73-80
   Google Scholar